FRESENIUS KABI

Intralipid®

20% (lipid injectable emulsion), for intravenous use
30% (lipid injectable emulsion), for intravenous use



The **longest-standing** lipid for parenteral nutrition (PN) in the US[1]

- FDA approved for over 40 years
- 100% soybean oil
- Provided in more than 200 million infusions* for adult and pediatric patients

Intralipid may be considered for patients requiring PN:[1]

- As a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD)
- When other lipid sources are not an option

INDICATION: Intralipid® is indicated as a source of calories and essential fatty acids for adult and pediatric patients requiring parenteral nutrition (PN) and as a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).

CONTRAINDICATIONS: Known hypersensitivity to egg, soybean, peanut, or any of the active ingredients or excipients in Intralipid. Severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride > 1,000 mg/dL).

Please see Important Safety Information on the reverse side.

Intralipid®

20% (lipid injectable emulsion), for intravenous use
30% (lipid injectable emulsion), for intravenous use

	Intralipid 20%		Intralipid 30%	
Composition	**Content per L**	**Content per mL**	**Content per L**	**Content per mL**
Soybean oil (g)	200	0.2	300	0.3
Osmolarity (mOsm/L)	260	0.26	200	0.2
Inorganic phosphate (mmol)	15	0.015	15	0.015
Total caloric value (kcal)	2000	2	3000	3

ORDERING INFORMATION					
Bag Size and Concentration	100 mL 20%	250 mL 20%	500 mL 20%	1000 mL 20%*	500 mL 30%*
NDC	65219-531-10	65219-533-25	65219-535-50	65219-539-10	65219-537-50
Bags/Case	10	10	12	6	12

*Intralipid Pharmacy Bulk Package is only indicated for use in pharmacy admixture program for the preparation of three-in-one or total nutrient admixtures

INDICATIONS AND USAGE

Intralipid is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition (PN) and as a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).

IMPORTANT SAFETY INFORMATION

Intralipid 20% Pharmacy Bulk Package (lipid injectable emulsion), for intravenous use and Intralipid 30% Pharmacy Bulk Package (lipid injectable emulsion), for intravenous use are for admixing use only and are not intended for direct intravenous administration.

Intralipid 30% (lipid injectable emulsion) Pharmacy Bulk Package must be combined with other PN fluids. Diluting Intralipid 30% with an intravenous fluid such as normal saline or other diluent does not produce a dilution that is equivalent in composition to Intralipid 10% or 20% intravenous lipid emulsions. Therefore, diluents other than dextrose and amino acids should not be used to prepare admixtures for direct intravenous administration. When Intralipid 30% is diluted, strictly adhere to the recommended total daily dosage; the hourly infusion rate should not exceed 0.125 g/kg/hour for neonates and infants.

Recommended dosage depends on age, energy expenditure, clinical status, body weight, tolerance, ability to metabolize and eliminate lipids, and consideration of additional energy given to the patient. Protect the admixed PN solution from light. Use a 1.2 micron in-line filter during administration.

Dosage for Intralipid 20%

Age	Nutritional Requirements	
	Initial Recommended Dosage	Maximum Dosage
Birth to 2 years of age (including preterm and term neonates)	0.5 g/kg/day	3 g/kg/day
Pediatric patients 2 to <12 years of age	1 to 2 g/kg/day	2.5 g/kg/day
Pediatric patients 12 to 17 years of age	1 g/kg/day	2 g/kg/day
Adults	1 g/kg/day (stable) ≤1 g/kg/day (critically ill)	2.5 g/kg/day

Intralipid is contraindicated in patients with:

- Known hypersensitivity to egg, soybean, or peanut, or any of the active ingredients or excipients
- Severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride > 1,000 mg/dL)

Risk of Clinical Decompensation with Rapid Infusion of Lipid Injectable Emulsion in Neonates and Infants: Acute respiratory distress, metabolic acidosis, and death after rapid infusion of lipid injectable emulsions have been reported. When Intralipid 30% is diluted, strictly adhere to the recommended total daily dosage; the hourly infusion rate should not exceed 0.125 g/kg/hour for neonates and infants.

Risk of Parenteral Nutrition-Associated Liver Disease (PNALD): Increased risk in patients who receive PN for extended periods of time, especially preterm neonates. Monitor liver function tests; if abnormalities occur consider discontinuation or dosage reduction.

Hypersensitivity Reactions: Monitor for signs or symptoms. Discontinue infusion if reactions occur.

Risk of Infections, Fat Overload Syndrome, Refeeding Syndrome, and Hypertriglyceridemia: Monitor for signs and symptoms; monitor laboratory parameters.

Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm neonates.

Most common adverse drug reactions (≥5%) from clinical trials in adults were nausea, vomiting, and pyrexia. Most common adverse drug reactions (≥5%) from clinical trials in pediatric patients were anemia, vomiting, increased gamma-glutamyltransferase, and cholestasis.

Vitamin K Antagonists (e.g., warfarin): Anticoagulant activity may be counteracted; increase monitoring of coagulation parameters.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

This Important Safety Information does not include all the information needed to use Intralipid safely and effectively. Please see full prescribing information, for intravenous use at at https://freseniuskabinutrition.com/Intralipid20PI or https://freseniuskabinutrition.com/Intralipid30PI

LEARN MORE AT: GETINTRALIPID.COM

Website: www.FreseniusKabiNutrition.com
To Order: 1.888.386.1300
For coding/billing info: https://www.freseniuskabinutrition.com/billing-coding/
Medical Information phone: 1.800.551.7176 (option 4)
Medical Information email: Nutrition.MedInfo.USA@fresenius-kabi.com

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

*data on file

REFERENCE: 1. Intralipid Prescribing Information, Fresenius Kabi USA, LLC. 2025

FRESENIUS KABI

Fresenius Kabi USA, LLC
Three Corporate Drive,
Lake Zurich, IL 60047
Phone: 1.888.386.1300
www.fresenius-kabi.com/us